7.76
+3.60%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oculis Holding
Its shares trade under the ticker OCS. It has been listed since 3 March 2023. In the fiscal year to 31 December 2024, it reported revenue of CHF 844,008 and a net loss of CHF 105.5m. At that date it held total assets of CHF 148.1m and shareholders' equity of CHF 90.3m.
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Mar 2023
- Employees
- 60
- Website
- oculis.com ↗
- Head office
- BAHNHOFSTRASSE 7, ZUG, V8, 6300
- Incorporated in
- V8
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Anthony RosenbergIndependent Chairman of the Board
- Dr. Riad SherifChief Executive Officer, Director, since 2017
- Ms. Sylvia CheungChief Financial Officer
- Mr. Pall JohannessonChief Business Officer, since 2024
- Ms. Christina AckermannIndependent Director
- Mr. Lionel CarnotIndependent Director
- Mr. Arshad KhananiIndependent Director
- Mr. Martijn KleijwegtIndependent Director, since 2023
- Ms. Geraldine O'KeeffeIndependent Director
- Mr. Robert WarnerIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oculis Holding AG employs 60 employees in the Health Care sector with a focus on ophthalmology treatments.
- OCS-01 targets diabetic macular edema using OPTIREACH technology for retinal treatment.
- OCS-02 is a topical biologic candidate for dry eye disease in a single chain antibody fragment form.
Weaknesses
- Oculis Holding AG has only 28 full-time employees in Zug, Zug, limiting operational capacity.
- The company's IPO on 3 March 2023 indicates recent market entry with limited financial history.
- Oculis Holding AG operates in the USA, Europe, and China but lacks detailed market share data.
Opportunities
- OCS-05 targets acute optic neuritis and other neuro-ophthalmic disorders like glaucoma and diabetic retinopathy.
- Expansion into the USA, Europe, and China offers growth potential in global eye care markets.
- Oculis Holding AG's focus on innovative treatments for DME and DED aligns with rising global eye health needs.
Threats
- Oculis Holding AG faces competition in the Health Care sector for ophthalmology treatments.
- The company's reliance on a few key products like OCS-01, OCS-02, and OCS-05 poses product dependency risk.
- Regulatory challenges in the USA, Europe, and China could impact product approvals and market access.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.